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TO THE EDITOR: We read with great interest the paper by Lee 
et al1 on the protective effect of proton pump inhibitors (PPIs) for 
survival in patients with gastroesophageal reflux disease (GERD) 
and idiopathic pulmonary fibrosis (IPF). The Authors reviewed 
a very large number of consecutive adult patients with IPF (n = 
786) and concluded that the prevalence of GERD is lower in Ko-
rean patients than in other countries and that PPI use for at least 4 
months may have a protective effect against IPF-related mortality. 
Although these data appear interesting, relevant limitations of 
this study were its retrospective nature and the fact that the diag-
nosis of GERD was not based on sound methods, in that only 18 
out of 107 patients had erosive esophagitis at endoscopy, while the 
remaining ones had non-erosive reflux disease (n = 66) or typi-
cal reflux symptoms without esophagogastroduodenoscopy (n = 
23). Moreover, no functional tests were performed (or described) 
in them. This is particularly relevant since it has been shown in 
previous series that a large number of IPF patients lack of GERD 
symptoms despite objective evidence of GERD at endoscopy or re-
flux monitoring.2-4 Indeed, in IPF patients a phenomenon so called 
“silent reflux” has been described and the consequent microaspira-
tion into the lungs has been mainly implicated in the pathogenesis 
of this condition.5 
In contrast with the paper of Lee et al,1 many previous studies 
have reported a higher prevalence of GERD in patients with IPF,2-4 
and this important relationship has been sustained by pathophysi-
ological investigations which allowed to detect objectively the pres-
ence of an abnormal reflux. For instance, Lee et al1 did not mention 
a study in IPF individuals performed with 24-hour impedance pH 
monitoring, which is nowadays considered to be the best test for 
measuring gastroesophageal reflux, also in case of atypical manifes-
tations.6-8 In this study, patients with IPF had significantly higher 
esophageal acid exposure and greater number of acid refluxes than 
controls, but also weakly acidic refluxes were remarkably increased.9 
Furthermore, more bile acids and pepsin were detected in both 
broncheoalveolar lavage fluid and saliva as strong confirmation 
of the risk of gastric aspiration in upper airways of these patients. 
Similarly, in an earlier pathophysiological study in a group of sclero-
derma patients with various degrees of pulmonary fibrosis based on 
high resolution computed tomography, not only acid but also weakly 
acidic refluxes were found much higher in patients with more severe 
than in those with mild or moderate pulmonary fibrosis.10 
In conclusion, we would like to emphasize that reflux monitor-
ing plays a fundamental role in confirming the presence of GERD 
in IPF patients and, therefore, the benefit of PPI use in them 
should be evaluated in carefully investigated subjects in order to 
provide stronger evidence that PPI may be helpful for their well-
being and survival. 
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